{
  "id": 15265637,
  "title": "Gilead chairman & CEO O’Day sells $2.2m in stock",
  "url": "https://urgent.news/2026/10/17/gilead-chairman-ceo-oday-sells-2-2m-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-17T19:46:19.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/gilead-chairman--ceo-oday-sells-22m-in-stock-93CH-4955543"
  },
  "original_language": "en",
  "account": "Daniel Patrick O’Day, Chairman and CEO of Gilead Sciences, sold 15,000 shares of the company’s stock on October 1, 2026, generating $2.2 million. Transactions occurred within a price range of $147.21 to $149.13, as per a pre-approved trading plan adopted on February 25, 2026. After the sale, O’Day still owned 566,683 shares of Gilead Sciences. This move comes as Gilead’s stock approaches its 52-week high, currently priced at $160.51, delivering a 29.5% return year-to-date. However, the stock seems overvalued according to InvestingPro analysis. Gilead Sciences reported better-than-expected earnings for Q2 2026, with adjusted earnings per share losing $6.75 and revenue reaching $7.8 billion. Key products like HIV, PrEP, oncology, and liver disease contributed significantly to the results. Despite $11.2 billion in IPR&D charges from recent acquisitions, the company remains focused on strategic partnerships and collaborations, such as a $10 million option with MacroGenics and a cost-sharing agreement with Assembly Biosciences for their herpes simplex virus program.",
  "summary": null,
  "key_points": [
    "Gilead CEO O’Day sold 15,000 shares, earning $2.2M",
    "Sale occurred within $147.21-$149.13 price range",
    "O’Day retained 566,683 shares after transaction"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}